Cargando…
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720354/ https://www.ncbi.nlm.nih.gov/pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 |
| _version_ | 1783619834813087744 |
|---|---|
| author | Brownlee, Wallace J |
| author_facet | Brownlee, Wallace J |
| author_sort | Brownlee, Wallace J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7720354 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77203542020-12-18 COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Brownlee, Wallace J Mult Scler Case Report and Clinical Commentary SAGE Publications 2020-08-07 2020-09 /pmc/articles/PMC7720354/ /pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Case Report and Clinical Commentary Brownlee, Wallace J COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title_full | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title_fullStr | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title_full_unstemmed | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title_short | COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? |
| title_sort | covid-19 and high-efficacy multiple sclerosis therapies: time for business as usual? |
| topic | Case Report and Clinical Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720354/ https://www.ncbi.nlm.nih.gov/pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211 |
| work_keys_str_mv | AT brownleewallacej covid19andhighefficacymultiplesclerosistherapiestimeforbusinessasusual |